Research
Hormonal
GLP-1 RAs were associated with a lower risk of several cardiovascular complications, including ischaemic heart disease, heart failure, arrhythmias, hypertension, stroke, and atrial fibrillation.
GLP-1 RAs may help reduce the risk of serious cardiovascular issues in obese patients without T2D.
StrongSupportsmedium confidence
GLP-1 RAs were also associated with a lower risk of acute kidney injury and allergic reactions.
Why this rating
Based on a large observational cohort study design.
Source
Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
Yu‐Nan Huang et al. · Diabetes Obesity and Metabolism · 2024
cohort · n=3729925Cited 34×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →